@article{fea1ade74d404b1797e851be21743584,
title = "Epirubicin and long-term heart failure risk in breast cancer survivors",
author = "Mahmood, {Syed S.} and Patel, {Ravi B.} and Javed Butler and Muthiah Vaduganathan",
note = "Funding Information: There is an enduring need for dedicated adjunctive CV safety programmes with centralized adjudication committees to accurately capture CV clinical endpoints, including HF, in emerging cancer trials for several reasons.13 First, many chemotherapy regimens in contemporary oncology have life-prolonging benefits, and CV adverse effects may be dose-or therapy-limiting. Second, new clinically-important CV toxicities are becoming identified with a broader range of cancer therapies.14 Third, relying on administrative health records may miss a significant proportion of patients who may ultimately develop chemotherapy-related cardiotoxicity. Fourth, similar CV safety programmes have been successfully employed in the evaluation of commonly used therapies (for instance, in diabetes mellitus and gout), and have yielded new knowledge regarding preventing CV events in these areas. Finally, as the population of patients being evaluated and treated for breast cancer becomes older with greater medical co-morbidities and as they are treated with combination chemotherapy regimens (with or without concomitant radiation therapy), competing cardiotoxic risks will become increasingly important to identify, manage, and potentially prevent. Cross-disciplinary collaboration between oncologists and cardiologists will continue to be necessary to develop effective therapies in cancer medicine with rigorous surveillance infrastructure to detect and appropriately manage potentially cardiotoxic adverse events. Conflict of interest: S.S.M. has been supported by the Sarnoff Cardiovascular Research Foundation. J.B. has received research support from the NIH and European Union and has been a consultant for Amgen, AstraZeneca, Bayer, Boehringer Ingel-heim, Bristol-Myers Squibb, CVRx, Janssen, Luitpold Pharmaceuticals, Medtronic, Merck, Novartis, Relypsa, Vifor Pharma, and ZS Pharma. M.V. is supported by the NHLBI T32 postdoctoral training grant (T32HL007604). R.B.P. has no conflicts of interest to declare.",
year = "2018",
month = oct,
doi = "10.1002/ejhf.1215",
language = "English (US)",
volume = "20",
pages = "1454--1456",
journal = "European Journal of Heart Failure",
issn = "1388-9842",
publisher = "John Wiley and Sons Ltd",
number = "10",
}
